Pulmonx (LUNG) Expected to Announce Earnings on Wednesday

Pulmonx (NASDAQ:LUNG - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $23.46 million for the quarter.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 63.69% and a negative net margin of 65.27%. The firm had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Price Performance

Shares of NASDAQ:LUNG traded up $0.02 during midday trading on Friday, reaching $3.34. 254,372 shares of the company's stock traded hands, compared to its average volume of 407,237. Pulmonx has a 1 year low of $2.50 and a 1 year high of $9.37. The company has a market cap of $134.47 million, a P/E ratio of -2.32 and a beta of 0.45. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.29 and a current ratio of 4.97. The company has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $5.10.

Insider Activity

In related news, Director Daniel P. Florin bought 23,321 shares of the company's stock in a transaction on Thursday, June 5th. The stock was bought at an average cost of $3.06 per share, for a total transaction of $71,362.26. Following the acquisition, the director directly owned 117,231 shares in the company, valued at $358,726.86. This represents a 24.83% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard Ferrari sold 8,000 shares of the firm's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $3.16, for a total value of $25,280.00. Following the completion of the sale, the director directly owned 87,024 shares of the company's stock, valued at $274,995.84. This trade represents a 8.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,388 shares of company stock valued at $136,044 in the last 90 days. 6.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LUNG shares. D. Boral Capital reiterated a "buy" rating and set a $17.00 target price on shares of Pulmonx in a research report on Thursday, May 1st. Citigroup decreased their price objective on Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 target price (down previously from $10.00) on shares of Pulmonx in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group reduced their target price on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.53.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.